Immune checkpoint inhibitors are emerging as a cornerstone melanoma treatment, with researchers uncovering how gut microbiota, immune cell interactions, and tumor microenvironment factors determine therapy success. New studies reveal that probiotics, B cell vesicles, and antibiotics significantly influence whether patients respond to checkpoint blockade, while certain melanoma types like uveal remain resistant.
·Probiotic ingredients can reprogram immune cells to attack tumors more effectively
·Gut microbiome composition predicts which melanoma patients will respond to checkpoint inhibitors
·B cell extracellular vesicles directly influence melanoma's susceptibility to immunotherapy
·Metastatic uveal melanoma shows poor response to checkpoint inhibitors despite success in cutaneous melanoma
·Checkpoint therapy is expanding beyond melanoma to treat non-melanoma skin cancers
drawn from Frontiers, EurekAlert!, Nature, Docwire News · updated 2d ago